This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018] Europ J Cancer. 2018; 103:356–387FerlayJColombetMSoerjomataramICancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018]Europ J Cancer201810335638710.1016/j.ejca.2018.07.00530100160Search in Google Scholar
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7–30SiegelRLMillerKDJemalACancer Statistics, 2017CA Cancer J Clin201767173010.3322/caac.2138728055103Search in Google Scholar
Garavello W, Bertuccio P, Levi F, et al. The oral cancer epidemic in central and eastern Europe. Int J Cancer. 2010; 127(1):160–171GaravelloWBertuccioPLeviFThe oral cancer epidemic in central and eastern EuropeInt J Cancer2010127116017110.1002/ijc.2501919882710Search in Google Scholar
Taher AN. Head and Neck Cancer: Closer Look at Patients Quality of Life. J Cancer Ther. 2016; 7:121–128TaherANHead and Neck Cancer: Closer Look at Patients Quality of LifeJ Cancer Ther2016712112810.4236/jct.2016.72014Search in Google Scholar
Elting LS, Chang YC. Costs of Oral Complications of Cancer Therapies: Estimates and a Blueprint for Future Study. JNCI Monographs, 2019; 2019(53): lgz010EltingLSChangYCCosts of Oral Complications of Cancer Therapies: Estimates and a Blueprint for Future StudyJNCI Monographs2019201953lgz01010.1093/jncimonographs/lgz01031425598Search in Google Scholar
PDQ® Supportive and Palliative Care Editorial Board. PDQ Oral Complications of Chemotherapy and Head/Neck Radiation. Bethesda, MD: National Cancer Institute. Updated <12/16/2016>.PDQ® Supportive and Palliative Care Editorial BoardPDQ Oral Complications of Chemotherapy and Head/Neck RadiationBethesda, MDNational Cancer InstituteUpdated <12/16/2016>.Search in Google Scholar
Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer. 2017; 25:1713–1739VigariosEEpsteinJBSibaudVOral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitorsSupport Care Cancer2017251713173910.1007/s00520-017-3629-428224235Search in Google Scholar
Watters AL, Epstein JB, Agulnik M. Oral complications of targeted cancer therapies: a narrative literature review. Oral Oncol. 2011; 47(6):441–8WattersALEpsteinJBAgulnikMOral complications of targeted cancer therapies: a narrative literature reviewOral Oncol2011476441810.1016/j.oraloncology.2011.03.02821514211Search in Google Scholar
Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011; 19:1079–95 doi:10.1007/s00520-011-1197-6LacoutureMEAnadkatMJBensadounRJClinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicitiesSupport Care Cancer20111910799510.1007/s00520-011-1197-6312870021630130Open DOISearch in Google Scholar
Rapoport BL, van Eeden R, Sibaud V, et al. Supportive care for patients undergoing immunotherapy. Support Care Cancer. 2017; 25(10):3017–3030RapoportBLvan EedenRSibaudVSupportive care for patients undergoing immunotherapySupport Care Cancer201725103017303010.1007/s00520-017-3802-928707167Search in Google Scholar
Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016; 13(8):473–86 doi:10.1038/nrclinonc.2016.58BoutrosCTarhiniARoutierESafety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combinationNat Rev Clin Oncol20161384738610.1038/nrclinonc.2016.5827141885Open DOISearch in Google Scholar
Nicolatou-Galitis O, Kouri M, Papadopoulou E, et al. Osteonecrosis of the jaw related to nonantiresorptive medications: a systematic review. Support Care Cancer. 2019; 27(2):383–394Nicolatou-GalitisOKouriMPapadopoulouEOsteonecrosis of the jaw related to nonantiresorptive medications: a systematic reviewSupport Care Cancer201927238339410.1007/s00520-018-4501-x30353228Search in Google Scholar
Davies M, Duffield EA. Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. Immunotargets Ther. 2017; 6:51–71 doi:10.2147/ITT.S141577DaviesMDuffieldEASafety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse eventsImmunotargets Ther20176517110.2147/ITT.S141577558492028894725Open DOISearch in Google Scholar
Lalla, RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014; 120:1453–61 doi:10.1002/cncr.28592LallaRVBowenJBaraschAMASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapyCancer201412014536110.1002/cncr.28592416402224615748Open DOISearch in Google Scholar
Zeller JL. High suicide risk found for patients with head and neck cancer. JAMA. 2006; 296:1716–1717ZellerJLHigh suicide risk found for patients with head and neck cancerJAMA20062961716171710.1001/jama.296.14.171617032977Search in Google Scholar
Epstein JB, Thariat J, Bensadoun RJ, et al. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin. 2012; 62(6):400–22 doi:10.3322/caac.21157EpsteinJBThariatJBensadounRJOral complications of cancer and cancer therapy: from cancer treatment to survivorshipCA Cancer J Clin20126264002210.3322/caac.2115722972543Open DOISearch in Google Scholar
Saraswat N, Sood A, Kumar D, et al. Clinical Profile of Cutaneous Adverse Effects of Epidermal Growth Factor Receptor Inhibitors: A Prospective Observational Study of 76 Cases. Indian Dermatol Online J. 2019; 10(3):251–255 doi:10.4103/idoj.IDOJ_325_18SaraswatNSoodAKumarDClinical Profile of Cutaneous Adverse Effects of Epidermal Growth Factor Receptor Inhibitors: A Prospective Observational Study of 76 CasesIndian Dermatol Online J201910325125510.4103/idoj.IDOJ_325_18653607631149566Open DOISearch in Google Scholar
Nicolatou-Galitis O, Kouloulias V, Sotiropoulou-Lountou A, et al. Oral Mucositis, Pain and Xerostomia in 135 Head and Neck Cancer Patients Receiving Radiotherapy with or without Chemotherapy. The Open Cancer Journal. 2011; 4:7–17Nicolatou-GalitisOKoulouliasVSotiropoulou-LountouAOral Mucositis, Pain and Xerostomia in 135 Head and Neck Cancer Patients Receiving Radiotherapy with or without ChemotherapyThe Open Cancer Journal2011471710.2174/1874079001104010007Search in Google Scholar
Brailo V, Boras VV, Juras DV, et al. Oral Side Effects of Head and Neck Irradiation. 2017; http://dx.doi.org/10.5772/intechopen.68961BrailoVBorasVVJurasDVOral Side Effects of Head and Neck Irradiation2017http://dx.doi.org/10.5772/intechopen.6896110.5772/intechopen.68961Search in Google Scholar
Bowen J, Al-Dasooqi N, Bossi P, et al. The pathogenesis of mucositis: updated perspectives and emerging targets. Support Care Cancer. 2019; 27:4023–4033BowenJAl-DasooqiNBossiPThe pathogenesis of mucositis: updated perspectives and emerging targetsSupport Care Cancer2019274023403310.1007/s00520-019-04893-z31286231Search in Google Scholar
Lalla RV, Brennan MT, Gordon SM, et al. Oral Mucositis Due to High-Dose Chemotherapy and/or Head and Neck Radiation Therapy. JNCI Monographs. 2019; 2019(53):lgz011LallaRVBrennanMTGordonSMOral Mucositis Due to High-Dose Chemotherapy and/or Head and Neck Radiation TherapyJNCI Monographs2019201953lgz011Search in Google Scholar
Lalla RV, Saunders DP, Peterson DE. Chemotherapy or radiation-induced oral mucositis. Dent. Clin. North Am. 2014; 58:341–9LallaRVSaundersDPPetersonDEChemotherapy or radiation-induced oral mucositisDent. Clin. North Am201458341910.1016/j.cden.2013.12.00524655526Search in Google Scholar
Sroussi HY, Epstein J, Bensadoun RJ, et al. Common oral implications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease and osteoradionecrosis. Cancer Med. 2017; 6(12):2918–31 doi:10.1002/cam4SroussiHYEpsteinJBensadounRJCommon oral implications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease and osteoradionecrosisCancer Med201761229183110.1002/cam4Open DOISearch in Google Scholar
Bressan V, Stevanin S, Bianchi M, et al. The effects of swallowing disorders, dysgeusia, oral mucositis and xerostomia on nutritional status, oral intake and weight loss in head and neck cancer patients: A systematic review. Cancer Treat Rev. 2016; 45:105–19 doi:10.1016/j.ctrv.2016.03.006]BressanVStevaninSBianchiMThe effects of swallowing disorders, dysgeusia, oral mucositis and xerostomia on nutritional status, oral intake and weight loss in head and neck cancer patients: A systematic reviewCancer Treat Rev2016451051910.1016/j.ctrv.2016.03.006Open DOISearch in Google Scholar
Vissink A, Jansma J, Spijkervet FKL, et al. Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 2003; 14(3):199–212VissinkAJansmaJSpijkervetFKLOral sequelae of head and neck radiotherapyCrit Rev Oral Biol Med200314319921210.1177/154411130301400305Search in Google Scholar
Lalla RV, Treister N, Sollecito T, et al. Oral complications at six months after radiation therapy for head and neck cancer. Oral Dis. 2017; 23(8):1134–43 doi:10.1111/odi.12710LallaRVTreisterNSollecitoTOral complications at six months after radiation therapy for head and neck cancerOral Dis201723811344310.1111/odi.12710Open DOISearch in Google Scholar
Elad S, Zadik Y. Chronic oral mucositis after radiotherapy to the head and neck: a new insight. Support Care Cancer. 2016; 24:4825–30 doi:10.1007/s00520-016-3337-5EladSZadikYChronic oral mucositis after radiotherapy to the head and neck: a new insightSupport Care Cancer20162448253010.1007/s00520-016-3337-5Open DOISearch in Google Scholar
Ang KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522] J. Clin. Oncol. 2014; 32:2940–50AngKKZhangQRosenthalDIRandomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522J. Clin. Oncol.20143229405010.1200/JCO.2013.53.5633Search in Google Scholar
Price TJ, Peeters M, Kim TW, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): A randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014; 15: 569–579PriceTJPeetersMKimTWPanitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): A randomised, multicentre, open-label, non-inferiority phase 3 studyLancet Oncol20141556957910.1016/S1470-2045(14)70118-4Search in Google Scholar
Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus Cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomized trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010; 11:21–28BonnerJAHarariPMGiraltJRadiotherapy plus Cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomized trial, and relation between cetuximab-induced rash and survivalLancet Oncol201011212810.1016/S1470-2045(09)70311-0Search in Google Scholar
Magrini SM, Buglione M, Corvò R, et al. Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial. J Clin Oncol. 2016; 34:427–435MagriniSMBuglioneMCorvòRCetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trialJ Clin Oncol20163442743510.1200/JCO.2015.63.167126644536Search in Google Scholar
Pryor DI, Burmeister E, Burmeister BH, et al. Distinct patterns of stomatitis with concurrent cetuximab and radiotherapy for head and neck squamous cell carcinoma. Oral Oncol. 2011; 47:984–987PryorDIBurmeisterEBurmeisterBHDistinct patterns of stomatitis with concurrent cetuximab and radiotherapy for head and neck squamous cell carcinomaOral Oncol20114798498710.1016/j.oraloncology.2011.07.02321852185Search in Google Scholar
De Sanctis V, Bossi P, Sanguineti G, et al. Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements. Crit Rev Oncol Hematol. 2016; 100:147–66] doi:10.1016/j.critrevonc.2016.01.010De SanctisVBossiPSanguinetiGMucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statementsCrit Rev Oncol Hematol20161001476610.1016/j.critrevonc.2016.01.01026947812Open DOISearch in Google Scholar
Zhao B, Zhao H, Zhao J. Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events. J Immunother Cancer. 2018; 6(1):101 doi:10.1186/s40425-018-0421-zZhaoBZhaoHZhaoJSerious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse eventsJ Immunother Cancer20186110110.1186/s40425-018-0421-z617117330285872Open DOISearch in Google Scholar
Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015; 373:1803–1813MotzerRJEscudierBMcDermottDFNivolumab versus everolimus in advanced renal-cell carcinomaN Engl J Med20153731803181310.1056/NEJMoa1510665571948726406148Search in Google Scholar
Lederhandler MH, Ho A, Brinster N, et al. Severe Oral Mucositis: A Rare Adverse Event of Pembrolizumab. J Drugs Dermatol. 2018; 17(7):807–809LederhandlerMHHoABrinsterNSevere Oral Mucositis: A Rare Adverse Event of PembrolizumabJ Drugs Dermatol2018177807809Search in Google Scholar
Bonomi M, Batt K. Supportive Management of Mucositis and Metabolic Derangements in Head and Neck Cancer Patients. Cancers 2015; 7:1743–1757BonomiMBattKSupportive Management of Mucositis and Metabolic Derangements in Head and Neck Cancer PatientsCancers201571743175710.3390/cancers7030862458679526404378Search in Google Scholar
Cramer JD, Johnson JT, Nilsen ML. Pain in Head and Neck Cancer Survivors: Prevalence, Predictors, and Quality-of-Life Impact. Otolaryngol Head Neck Surg. 2018; 159(5):853–8 doi:10.1177/0194599818783964CramerJDJohnsonJTNilsenMLPain in Head and Neck Cancer Survivors: Prevalence, Predictors, and Quality-of-Life ImpactOtolaryngol Head Neck Surg20181595853810.1177/019459981878396429943677Open DOISearch in Google Scholar
Jackson LK, Johnson DB, Sosman JA, et al. Oral health in oncology: impact of immunotherapy. Support Care Cancer. 2015; 23(1):1–3 doi:10.1007/s00520-014-2434-6JacksonLKJohnsonDBSosmanJAOral health in oncology: impact of immunotherapySupport Care Cancer20152311310.1007/s00520-014-2434-625216852Open DOISearch in Google Scholar
Epstein JB, Wilkie DJ, Fischer DJ, et al. Neuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapy. Head Neck Oncol. 2009; 1:26 doi:10.1186/1758-3284-1-26EpsteinJBWilkieDJFischerDJNeuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapyHead Neck Oncol200912610.1186/1758-3284-1-26271796319594943Open DOISearch in Google Scholar
Lalla RV, Latortue MC, Hong CH, et al. A systematic review of oral fungal infections in patients receiving cancer therapy. Support Care Cancer. 2010; 18:985–992LallaRVLatortueMCHongCHA systematic review of oral fungal infections in patients receiving cancer therapySupport Care Cancer20101898599210.1007/s00520-010-0892-z291479720449755Search in Google Scholar
Nicolatou-Galitis O, Athanassiadou P, Kouloulias V, et al. Herpes simplex virus-1 (HSV-1) infection in radiation-induced oral mucositis. Support Care Cancer 2006; 14:753–762.Nicolatou-GalitisOAthanassiadouPKoulouliasVHerpes simplex virus-1 (HSV-1) infection in radiation-induced oral mucositisSupport Care Cancer20061475376210.1007/s00520-005-0006-516402233Search in Google Scholar
Yarom N, Sroussi H, Elad S. Orofacial Pain in Patients with Cancer and Mucosal Diseases. Contemporary Oral Medicine. 2018; DOI: 10.1007/978-3-319-28100-1_39-1YaromNSroussiHEladSOrofacial Pain in Patients with Cancer and Mucosal DiseasesContemporary Oral Medicine201810.1007/978-3-319-28100-1_39-1Open DOISearch in Google Scholar
Viet CT, Corby PM, Akinwande A, et al. Review of Preclinical studies on treatment of Mucositis and Associated Pain. J Dent Res. 2014; 93:868–75.VietCTCorbyPMAkinwandeAReview of Preclinical studies on treatment of Mucositis and Associated PainJ Dent Res2014938687510.1177/0022034514540174421324824943201Search in Google Scholar
Kouri M, Skapinakis P, Damigos D. Effects of the drugs and interventions, used for the management of cancer treatment-related oral mucositis, on the induced oral pain. The internet journal of Pain, Symptom Control and Palliative Care 2012; 9 (1) doi:10.5580/2c2bKouriMSkapinakisPDamigosDEffects of the drugs and interventions, used for the management of cancer treatment-related oral mucositis, on the induced oral painThe internet journal of Pain, Symptom Control and Palliative Care20129110.5580/2c2bOpen DOISearch in Google Scholar
Vadalouca A, Raptis E, Moka E, et al. Pharmacological Treatment of Neuropathic Cancer Pain: A Comprehensive Review of the Current Literature. Pain Pract. 2012; 12:219–251VadaloucaARaptisEMokaEPharmacological Treatment of Neuropathic Cancer Pain: A Comprehensive Review of the Current LiteraturePain Pract20121221925110.1111/j.1533-2500.2011.00485.x21797961Search in Google Scholar
Carrozzo M, Eriksen JG, Bensadoun RJ, et al. Oral Mucosal Injury Caused by Targeted Cancer Therapies. J Natl Cancer Inst Monogr. 2019; 2019(53). pii: lgz012 doi:10.1093/jncimonographs/lgz012CarrozzoMEriksenJGBensadounRJOral Mucosal Injury Caused by Targeted Cancer TherapiesJ Natl Cancer Inst Monogr2019201953pii: lgz01210.1093/jncimonographs/lgz01231425602Open DOISearch in Google Scholar
Villa A, Sonis S. Toxicities associated with head and neck cancer treatment and oncology-related clinical trials. Curr Probl Cancer. 2016; 40:244–257VillaASonisSToxicities associated with head and neck cancer treatment and oncology-related clinical trialsCurr Probl Cancer20164024425710.1016/j.currproblcancer.2016.06.00127520848Search in Google Scholar
Villa A, Wolff A, Narayana N, et al. World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction Oral Diseases. 2016; 22, 365–382VillaAWolffANarayanaNWorld Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunctionOral Diseases20162236538210.1111/odi.1240226602059Search in Google Scholar
Pinna R, Campus G, Cumbo E, et al. Xerostomia induced by radiotherapy: an overview of the physiopathology, clinical evidence, and management of the oral damage. Therapeutics and Clinical Risk Management 2015; 11:171–188PinnaRCampusGCumboEXerostomia induced by radiotherapy: an overview of the physiopathology, clinical evidence, and management of the oral damageTherapeutics and Clinical Risk Management20151117118810.2147/TCRM.S70652432583025691810Search in Google Scholar
Konings AWT, Coppes RP, Vissink A. On the mechanism of salivary gland radiosensitivity. Int. J. Radiation Oncology Biol Phys 2005; 62(4):1187–1194KoningsAWTCoppesRPVissinkAOn the mechanism of salivary gland radiosensitivityInt. J. Radiation Oncology Biol Phys20056241187119410.1016/j.ijrobp.2004.12.05115990024Search in Google Scholar
Adel N. Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies. Am J Manag Care. 2017; 23(14 Suppl):259–265AdelNOverview of chemotherapy-induced nausea and vomiting and evidence-based therapiesAm J Manag Care20172314 Suppl259265Search in Google Scholar
Moreno J, Sahade M, del Giglio A. Low-dose granisetron for prophylaxis of acute chemotherapy-induced nausea and vomiting: a pilot study. Support Care Cancer. 2005; 13:850–853.MorenoJSahadeMdel GiglioALow-dose granisetron for prophylaxis of acute chemotherapy-induced nausea and vomiting: a pilot studySupport Care Cancer20051385085310.1007/s00520-005-0817-415838618Search in Google Scholar
Jain T, Bhandari A, Ram V, et al. Drug interactions and adverse drug reactions in hospitalized psychiatric patients: a critical element in providing safe medication use. German J Psychiatry. 2011; 14:26–34]JainTBhandariARamVDrug interactions and adverse drug reactions in hospitalized psychiatric patients: a critical element in providing safe medication useGerman J Psychiatry2011142634Search in Google Scholar
Ware MA, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesthesia & Analgesia 2010; 110:604–10]WareMAFitzcharlesMAJosephLShirYThe effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trialAnesthesia & Analgesia20101106041010.1213/ANE.0b013e3181c76f7020007734Search in Google Scholar
Yamagishi H, Kawaguchi M. Characterization of centraland peripheral-type benzodiazepine receptors in rat salivary glands. Biochem Pharmacol. 1998; 55: 209–214YamagishiHKawaguchiMCharacterization of centraland peripheral-type benzodiazepine receptors in rat salivary glandsBiochem Pharmacol19985520921410.1016/S0006-2952(97)00433-4Search in Google Scholar
Wang X, Zhang ZY, Wang J, et al. Pharmacokinetics, safety, and tolerability of rolapitant administered intravenously following single ascending and multiple ascending doses in healthy subjects. Clin Pharmacol Drug Dev. 2019;8(2):160–171WangXZhangZYWangJPharmacokinetics, safety, and tolerability of rolapitant administered intravenously following single ascending and multiple ascending doses in healthy subjectsClin Pharmacol Drug Dev20198216017110.1002/cpdd.58029905976Search in Google Scholar
Godoy T, Riva A, Ekström J. Atypical antipsychotics-effects of amisulpride on salivary secretion and on clozapine-induced sialorrhea. Oral Dis. 2012; 18(7):680–91 doi:10.1111/j.1601-0825.2012.01926.xGodoyTRivaAEkströmJAtypical antipsychotics-effects of amisulpride on salivary secretion and on clozapine-induced sialorrheaOral Dis20121876809110.1111/j.1601-0825.2012.01926.x22458406Open DOISearch in Google Scholar
Schiff E, Mogilner JG, Sella E, et al. Hypnosis for postradiation xerostomia in head and neck cancer patients: a pilot study. Pain Symptom Manage 2009; 37:1086–1092SchiffEMogilnerJGSellaEHypnosis for postradiation xerostomia in head and neck cancer patients: a pilot studyPain Symptom Manage2009371086109210.1016/j.jpainsymman.2008.07.00519186028Search in Google Scholar
Hovan AJ, Williams M, Stevenson-Moore P, et al. A systematic review of dysgeusia induced by cancer therapies. Support Care Cancer 2010; 18:1081–1087HovanAJWilliamsMStevenson-MoorePA systematic review of dysgeusia induced by cancer therapiesSupport Care Cancer2010181081108710.1007/s00520-010-0902-120495984Search in Google Scholar
Nicolatou-Galitis O, Velegraki A, Sotiropoulou-Lontou A, et al. Effect of fluconazole antifungal prophylaxis on oral mucositis in head and neck cancer patients receiving radiotherapy. Support Care Cancer. 2006; 14:44–51Nicolatou-GalitisOVelegrakiASotiropoulou-LontouAEffect of fluconazole antifungal prophylaxis on oral mucositis in head and neck cancer patients receiving radiotherapySupport Care Cancer200614445110.1007/s00520-005-0835-215947956Search in Google Scholar
Wolff A, Joshi RK, Ekström J et al. A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI. Drugs R D. 2017; 17:1–28WolffAJoshiRKEkströmJA Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VIDrugs R D20171712810.1007/s40268-016-0153-9531832127853957Search in Google Scholar
Turner L, Mupparapu M, Akintoye SO. Review of the complications associated with treatment of oropharyngeal cancer: A guide to the dental practitioner. Quintessence Int 2013; 44(3):267–279TurnerLMupparapuMAkintoyeSOReview of the complications associated with treatment of oropharyngeal cancer: A guide to the dental practitionerQuintessence Int2013443267279Search in Google Scholar
Elad S, Zadik Y, Hewson I, et al. A Systematic Review of Viral infections Associated with oral involvement in cancer patients; a spotlight on herpesviridea. Support Care Cancer. 2010; 18(8):993–1006EladSZadikYHewsonIA Systematic Review of Viral infections Associated with oral involvement in cancer patients; a spotlight on herpesvirideaSupport Care Cancer2010188993100610.1007/s00520-010-0900-320544224Search in Google Scholar
Elad S, Ranna V, Ariyawardana A, et al. A systematic review of oral herpetic viral infections in cancer patients: commonly used outcome measures and interventions. Support Care Cancer. 2017; 25(2):687–700 doi:10.1007/s00520-016-3477-7EladSRannaVAriyawardanaAA systematic review of oral herpetic viral infections in cancer patients: commonly used outcome measures and interventionsSupport Care Cancer201725268770010.1007/s00520-016-3477-727853930Open DOISearch in Google Scholar
Panghal M, Kaushal V, Kadayan S, et al. Incidence and risk factors for infection in oral cancer patients undergoing different treatments protocols. BMC Oral Health. 2012; 12:22. doi:10.1186/1472-6831-12-22PanghalMKaushalVKadayanSIncidence and risk factors for infection in oral cancer patients undergoing different treatments protocolsBMC Oral Health2012122210.1186/1472-6831-12-22349918422817766Open DOISearch in Google Scholar
Uhlen MM, Tveit AB, Stenhagen KR, et al. Self-induced vomiting and dental erosion-a clinical study. BMC Oral Health. 2014; 14:92 doi:10.1186/1472-6831-14-92UhlenMMTveitABStenhagenKRSelf-induced vomiting and dental erosion-a clinical studyBMC Oral Health2014149210.1186/1472-6831-14-92412559625069878Open DOISearch in Google Scholar
Galitis E, Droukas V, Tzakis M, et al. Trismus and reduced quality of life in patients with oral squamous cell carcinoma, who received postoperative radiotherapy alone or combined with chemotherapy. Forum of Clinical Oncology. 2017; 8(1):29–36GalitisEDroukasVTzakisMTrismus and reduced quality of life in patients with oral squamous cell carcinoma, who received postoperative radiotherapy alone or combined with chemotherapyForum of Clinical Oncology201781293610.1515/fco-2015-0023Search in Google Scholar
Dijkstra PU, Huisman PM, Roodenburg JLN. Criteria for trismus in head and neck oncology. Int J Oral Maxillofac Surg 2006; 35:337–342DijkstraPUHuismanPMRoodenburgJLNCriteria for trismus in head and neck oncologyInt J Oral Maxillofac Surg20063533734210.1016/j.ijom.2005.08.00116280237Search in Google Scholar
Dhanda J1, Pasquier D2, Newman L3, et al. Current Concepts in Osteoradionecrosis after Head and Neck Radiotherapy. Clin Oncol (R Coll Radiol). 2016; 28(7):459–66 doi:10.1016/j.clon.2016.03.002DhandaJPasquierDNewmanLCurrent Concepts in Osteoradionecrosis after Head and Neck RadiotherapyClin Oncol (R Coll Radiol)20162874596610.1016/j.clon.2016.03.00227038708Open DOISearch in Google Scholar
Spijkervet FKL, Brennan MT, Peterson DE, et al. Research Frontiers in Oral Toxicities of Cancer Therapies: Osteoradionecrosis of the Jaws. J Natl Cancer Inst Monogr. 2019; 2019(53): pii: lgz006 doi:10.1093/jncimonographs/lgz006SpijkervetFKLBrennanMTPetersonDEResearch Frontiers in Oral Toxicities of Cancer Therapies: Osteoradionecrosis of the JawsJ Natl Cancer Inst Monogr2019201953pii: lgz00610.1093/jncimonographs/lgz00631425599Open DOISearch in Google Scholar
Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg. 2014; 72(10):1938–1956 doi:10.1016/j.joms.2014.04.031RuggieroSLDodsonTBFantasiaJAmerican Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 updateJ Oral Maxillofac Surg201472101938195610.1016/j.joms.2014.04.03125234529Open DOISearch in Google Scholar
Nicolatou-Galitis O, Schiødt M, Mendes RA, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment Oral Surg Oral Med Oral Pathol Oral Radiol. 2019; 127(2):117–135 doi:10.1016/j.oooo.2018.09.008Nicolatou-GalitisOSchiødtMMendesRAMedication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatmentOral Surg Oral Med Oral Pathol Oral Radiol2019127211713510.1016/j.oooo.2018.09.00830393090Open DOISearch in Google Scholar
Nicolatou-Galitis O, Razis E, Galiti D, et al. Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving antiresorptives alone or combined with targeted therapies: report of 5 cases and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015; 120(6):699–706Nicolatou-GalitisORazisEGalitiDPeriodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving antiresorptives alone or combined with targeted therapies: report of 5 cases and literature reviewOral Surg Oral Med Oral Pathol Oral Radiol2015120669970610.1016/j.oooo.2015.08.00726455289Search in Google Scholar
Nicolatou-Galitis O, Papadopoulou E, Vardas E, et al. Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents. Oral Dis. 2020; doi:10.1111/odi.13294Nicolatou-GalitisOPapadopoulouEVardasEAlveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agentsOral Dis202010.1111/odi.1329432011077Open DOISearch in Google Scholar
Heifetz-Li JJ, Abdelsamie S, Campbell CB, et al. Systematic review of the use of pentoxifylline and tocopherol for the treatment of medication-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019; 128(5):491–7.e2 doi:10.1016/j.oooo.2019.08.004Heifetz-LiJJAbdelsamieSCampbellCBSystematic review of the use of pentoxifylline and tocopherol for the treatment of medication-related osteonecrosis of the jawOral Surg Oral Med Oral Pathol Oral Radiol201912854917.e210.1016/j.oooo.2019.08.00431488389Open DOISearch in Google Scholar
Fragulidis G, Pantiora E, Michalaki V, et al. Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient. J Oncol Pharm Pract. 2019; 25(2):487–491 doi:10.1177/1078155217738325FragulidisGPantioraEMichalakiVImmune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patientJ Oncol Pharm Pract201925248749110.1177/107815521773832529067858Open DOISearch in Google Scholar
Economopoulou P, Nicolatou-Galitis O, Kotsantis I, et al. Nivolumab-related lichen planus of the lip in a patient with head and neck cancer. Oral Oncology. 2020; http://doi.org/10.1016/j.oraloncology.2020.104623EconomopoulouPNicolatou-GalitisOKotsantisINivolumab-related lichen planus of the lip in a patient with head and neck cancerOral Oncology2020http://doi.org/10.1016/j.oraloncology.2020.10462310.1016/j.oraloncology.2020.10462332144002Search in Google Scholar
Cogen AL, Parekh V, Gangadhar T et al. Lichen planopilaris associated with pembrolizumab in a patient with metastatic melanoma. JAAD Case Rep. 2018; 4(2):132–134 doi:10.1016/j.jdcr.2017.12.002CogenALParekhVGangadharTLichen planopilaris associated with pembrolizumab in a patient with metastatic melanomaJAAD Case Rep20184213213410.1016/j.jdcr.2017.12.002578976129387763Open DOISearch in Google Scholar
Collins LK, Chapman MS, Carter JB, et al. Cutaneous adverse effects of the immune checkpoint inhibitors. Current Problems in Cancer. Curr Probl Cancer. 2017; 41(2):125–128 doi:10.1016/j.currproblcancer.2016.12.001CollinsLKChapmanMSCarterJBCutaneous adverse effects of the immune checkpoint inhibitorsCurrent Problems in Cancer. Curr Probl Cancer201741212512810.1016/j.currproblcancer.2016.12.00128190531Open DOISearch in Google Scholar
Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017; 28(2):368–376MenziesAMJohnsonDBRamanujamSAnti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumabAnn Oncol201728236837610.1093/annonc/mdw44327687304Search in Google Scholar
Wang H, Mustafa A, Liu S, et al. Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management. Front Pharmacol. 2019; 10:1254 doi:10.3389/fphar.2019.01254WangHMustafaALiuSImmune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to ManagementFront Pharmacol201910125410.3389/fphar.2019.01254681943431708780Open DOISearch in Google Scholar
Peterson DE, Boers-Doets CB, Bensadoun RJ, et al. Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2015; 26 Suppl 5:v139–51 doi:10.1093/annonc/mdv202PetersonDEBoers-DoetsCBBensadounRJManagement of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-upAnn Oncol201526Suppl 5v1395110.1093/annonc/mdv20226142468Open DOISearch in Google Scholar
Basile D, Di Nardo P, Corvaja C, et al. Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside. Cancers (Basel). 2019; 11(6): pii:E857 doi:10.3390/cancers11060857BasileDDi NardoPCorvajaCMucosal Injury during Anti-Cancer Treatment: From Pathobiology to BedsideCancers (Basel)2019116pii:E85710.3390/cancers11060857662728431226812Open DOISearch in Google Scholar
Larson PJ, Miaskowski C, MacPhail L, et al. The PRO-SELF Mouth Aware program: an effective approach for reducing chemotherapy-induced mucositis. Cancer Nurs. 1998; 21(4):263–268.LarsonPJMiaskowskiCMacPhailLThe PRO-SELF Mouth Aware program: an effective approach for reducing chemotherapy-induced mucositisCancer Nurs199821426326810.1097/00002820-199808000-000079691508Search in Google Scholar
Hong CHL, Gueiros LA, Fulton JS, et al. Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2019; 27(10):3949–3967 doi:10.1007/s00520-019-04848-4HongCHLGueirosLAFultonJSSystematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelinesSupport Care Cancer201927103949396710.1007/s00520-019-04848-431286232Open DOISearch in Google Scholar
Lopez BC, Esteve CG, Perez MGS. Dental treatment considerations in the chemotherapy patient. J Clin Exp Dent. 2010; 3:31–42LopezBCEsteveCGPerezMGSDental treatment considerations in the chemotherapy patientJ Clin Exp Dent201033142Search in Google Scholar
Caribé-Gomes F, Chimenos-Küstner E, López-López J, et al. Dental management of the complications of radio and chemotherapy in oral cancer. Med Oral. 2003; 8(3):178–187Caribé-GomesFChimenos-KüstnerELópez-LópezJDental management of the complications of radio and chemotherapy in oral cancerMed Oral200383178187Search in Google Scholar